

2009 CCS Guidelines for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease in the Adult
Disclosures of Conflict of Interest

Member	Has an affiliation with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline	Consulting fees/ Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Jacques Genest	Yes	AstraZeneca, GlaxoSmithKline, Merck Frosst, Pfizer, and/or Schering-Plough	None	AstraZeneca, Merck/Schering-Plough, and/or Resverlogix	None	None	None
Ruth McPherson	Yes	AstraZeneca, Merck Frosst, Pfizer, Oryx, and/or Schering-Plough	None	AstraZeneca, Merck Frosst, Pfizer, Oryx, and/or Schering-Plough	None	None	None
Jiri Frohlich	Yes	AstraZeneca, Merck Frosst, Pfizer, Schering-Plough, Oryx, and/or GlaxoSmithKline	None	AstraZeneca, Merck Frosst, Pfizer, Schering-Plough, Oryx, and/or GlaxoSmithKline	None	None	None
Todd Anderson	Yes	AstraZeneca, Pfizer, Merck, Schering, GlaxoSmithKline, and/or Eli Lilly	None	AstraZeneca, Pfizer, Merck, Schering, GlaxoSmithKline, and/or Eli Lilly	None	None	None
Norm Campbell	Yes	Bayer, Sanofi aventis, Biovail, Bristol-Myers Squibb, Pfizer, Novartis, Merck Frosst, Servier, Boehringer Ingleheim, and/or Schering-Plough	None	None	None	None	None
André Carpentier	Yes	AstraZeneca, GlaxoSmithKline, Merck Frosst, Pfizer, Schering-Plough	None	Aventis, AstraZeneca, GlaxoSmithKline, Merck-Frosst-Schering Plough, Novartis, Pfizer, Philips, Amsterdam Molecular Therapeutics	None	None	None
Patrick Couture	Yes	AstraZeneca, Merck Frosst, Merck-Schering, Pfizer, Solvay	None	Merck Frosst, Merck-Schering, Pfizer	None	None	None

2009 CCS Guidelines for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease in the Adult
Disclosures of Conflict of Interest

Member	Has an affiliation with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline	Consulting fees/ Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Robert Dufour	Yes	AstraZeneca, Bristol-Myers Squibb, Pfizer, Genzyme, Isis, and/or Merck Frosst	None	AstraZeneca, Bristol-Myers Squibb, Pfizer, Genzyme, Isis, and/or Merck Frosst	None	None	None
George Fodor	non disclosed						
Gordon A Francis	Yes	AstraZeneca, Merck Frosst, Oryx, Merck Frosst-Schering, Solvay Pharma	None	an unrestricted research grant from Pfizer Canada	None	None	None
Steven Grover	non disclosed						
Milan Gupta	Yes	AstraZeneca, Pfizer, Bristol-Myers Squibb, Novartis, Merck Frosst, Oryx, Solvay, Abbott, Schering-Plough	None	AstraZeneca, Pfizer, Merck Schering	None	None	None
Robert A Hegele	Yes	AstraZeneca, Pfizer, Merck Frosst, Solvay, Sepracor, Kowa, Roche, Schering, Merck-Schering	None	AstraZeneca, Pfizer, Merck Schering	None	None	None
David C Lau	non disclosed						
Lawrence Leiter	Yes	AstraZeneca, Merck Frosst, Merck Schering-Plough, Pfizer, Roche, and/or Solvay	None	AstraZeneca, Merck Frosst, Merck Schering-Plough, Pfizer, Roche, and/or Solvay	None	None	None
Gary F Lewis	Yes	AstraZeneca, Merck Frosst, Pfizer, Solvay Pharma, Eli Lilly, Merck-Schering	None	Amylin Pharmaceuticals, Pfizer	None	None	None
Eva Lonn	Yes	Merck, Schering-Plough, Pfizer, Abbott, AstraZeneca, and/or GlaxoSmithKline	None	Merck, Schering-Plough, Pfizer, Abbott, AstraZeneca, and/or GlaxoSmithKline	None	None	None
John Mancini	Yes	Merck Frosst, AstraZeneca, GlaxoSmithKline, Pfizer, Sanofi-aventis, Schering-Plough, Abbott/Solvay	None	Merck Frosst	None	None	None

2009 CCS Guidelines for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease in the Adult
Disclosures of Conflict of Interest

Member	Has an affiliation with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline	Consulting fees/ Honoraria	Officer, director, or in any other fiduciary role	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Dominic Ng	Yes	AstraZeneca, Merck Frosst, Schering-Plough, Sanofi-aventis, Pfizer, GlaxoSmithKline	None	None	None	None	None
Glen J Pearson	Yes	Astellas, AstraZeneca, Merck Frosst, Pfizer, Novartis, Roche, Sanofi-aventis, Schering-Plough	None	Fujisawa, Novartis, Merck Frosst	None	None	None
Allan Sniderman	Yes	Merck-Schering	None	AstraZeneca	None	None	None
James A Stone	Yes	AstraZeneca, Merck Frosst, Bristol-Myers Squibb, Novartis, Pfizer, Servier, Sanofi-aventis, Schering-Plough	None	None	None	None	None
Ehud Ur	Yes	Merck Frosst, AstraZeneca, Schering-Plough, and/or Pfizer	None	Merck Frosst, AstraZeneca, Schering-Plough, and/or Pfizer	None	None	None